AMH and premature menopause: Therefore, the discordance between a marker of follicular quantity, possibly represented by AMH, and a marker of stromal pathology, possibly represented by FAP, could provide a more nuanced assessment of a patient’s true biological ovarian age, supposedly in DOR with young age and/or women with premature ovarian insufficiency (POI).